ACUTE MYELOID LEUKEMIA, IN RELAPSE

This early-phase study tests a new treatment for acute myeloid leukemia (AML) that combines a personalized immune cell therapy with standard chemotherapy drugs. The therapy uses the patient's own immune cells, trained to attack the cancer, along with a vaccine to boost the immune…

This study tests a new drug called ARD103 in adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 49 participants will rece…

This early-phase study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to be…

This study tests whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 40 participants will receive the combination to see if it is safe and eff…

This early-phase study tests a new drug called C6 ceramide NanoLiposome (CNL) in 15 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that …

This study tests a new drug called AB8939 in people whose acute myeloid leukemia (AML) has returned or not responded to prior treatments. The main goal is to find a safe dose and see if the drug can shrink or control the cancer. About 78 adults will receive daily infusions, and r…

This early-stage study tests a combination of two drugs, bomedemstat and venetoclax, in adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy. The main goal is to find the safest dose and understand side effects. About 18 participants will b…

This study tests a new treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It combines special immune cells (CIML NK cells) with a drug called atezolizumab. The goal is to find a safe dose and see if the combination can …

This early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…

This early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…

This early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This early-stage study tests a pre-made immune cell therapy (MT-401-OTS) for people aged 65+ with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor T-cells designed to attack multiple cancer-related targets. The main goals are to check…

This study will follow 4,000 people whose acute myeloid leukemia has come back or not responded to treatment. Researchers will collect information on which treatments are used and how long patients live, without giving any new medicine. The goal is to learn what works best in eve…